Orogen Therapeutics Collaborates with Chemspace and Enamine to Develop Next-Generation AI-Enabled DNA-Encoded Libraries for Drug Discovery

Orogen Therapeutics, a private drug discovery company focused on AI-enabled DNA-encoded libraries (DEL), has entered into a strategic collaboration with Chemspace and Enamine to develop next-generation DELs. This partnership aims to integrate the vast chemical space of Enamine’s REAL (REadily AccessibLE) compounds, which represent the world's largest make-on-demand small molecule collection, with Orogen’s advanced DEL and AI technologies and Chemspace’s computational and synthetic expertise. The collaboration will leverage Enamine’s REAL Space principles, known for their rapid and cost-effective synthesis using validated parallel protocols and in-stock building blocks. Combining this with Orogen’s FocusDEL™ technology, which enhances hit yields by enabling enriched screening of immense chemical spaces, and Chemspace’s computational chemistry tools, the teams aim to design, build, and test novel DELs that can accelerate the early stages of small molecule drug discovery. Mark Pykett, Orogen’s CEO, expressed enthusiasm about the partnership, stating that it brings together the strengths of the three companies to advance DEL-based drug development. Sven Wagner, Vice President of Partnerships at Enamine, highlighted the value of DEL screening in efficiently exploring large chemical spaces for new therapies, particularly in areas like immuno-inflammatory disorders. Artem Evdokimot, Orogen’s Head of Research, anticipates that the collaboration will provide much-needed next-generation DELs, simplifying the synthesis and optimization of off-DNA compounds and enhancing the discovery process for novel, safe, and effective medicines. Under the agreement, Chemspace and Enamine will handle the synthesis and analytical validation of the new REAL-driven DELs, while Orogen will screen these libraries against multiple biological targets. Both Chemspace and Enamine see this as an opportunity to expand their product and service offerings, while Orogen envisions discovering multiple novel small molecule candidates in key therapeutic areas. Chemspace’s CEO, Olga Tarkhanova, explained that by merging the Chemspace/Enamine chemical space with Orogen’s DEL platform, the collaboration addresses a critical bottleneck in moving from encoded hits to optimized compounds, thereby speeding up the drug discovery cycle. Industry experts view this partnership as a significant step forward in drug discovery, emphasizing the potential to streamline and enhance the identification of new therapeutic candidates. The integration of AI, DEL technology, and make-on-demand chemistry is seen as a promising approach to overcome traditional barriers in the early stages of drug development. Company Profiles: Orogen Therapeutics: Orogen Therapeutics is dedicated to delivering breakthrough clinical solutions for patients with serious unmet medical needs. Their proprietary platform integrates DELs with massive chemical diversity, virtual screening, and AI-driven computation to derive novel drug candidates efficiently. For more information, visit www.orogentx.com. Chemspace: Chemspace specializes in drug discovery services, offering a suite of computational chemistry tools, bioinformatics, and machine learning-based services to explore ultra-large chemical spaces. Their integrated projects provide a seamless path from hit identification to pre-clinical studies. For more information, visit https://chem-space.com. Enamine: Enamine is a leading provider of chemical compounds and an integrated discovery Contract Research Organization (CRO). They offer unique partnering opportunities and combine in-house screening compounds with a comprehensive platform of discovery services in bioinformatics, biology, and chemistry. For more information, visit enamine.net. The forward-looking statements in this announcement reflect the companies' optimism and strategic vision, but they are subject to various uncertainties and risks, including the challenges of integrating different technologies and achieving expected outcomes in drug discovery. Despite these, the collaboration is poised to make a substantial impact in advancing new treatments for a range of conditions.